No Data
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
Express News | HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $8
Purple Biotech Reveals Optimistic Cancer Treatment Data
Purple Biotech Reported New Biomarker Findings From Phase 2 Study Of Its Lead Oncology Therapeutic Candidate CM24 In Combination With Bristol Myers Squibb's Nivolumab Plus Standard Of Care Chemotherapy
Express News | Purple Biotech Reports Additional Positive Interim Data From Its Randomized Phase 2 Study With Its Lead Oncology Therapeutic Candidate Cm24
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending